of cases, 2 – 4 their reported frequency in adult HGGs (1%–3%) 5 – 8 is comparable to that of other solid tumor types, such as colorectal carcinoma (3%), 9 NSCLC (3%), 10 ovarian carcinoma (0.5%), 11 and squamous cell carcinoma of the head and
Search Results
Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma
Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya, and George Ansstas
Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation
Rachel L. Mitchell, Cory Kosche, Kelly Burgess, Shreya Wadhwa, Lela Buckingham, Ritu Ghai, Jacob Rotmensch, Oleksandra Klapko, and Lydia Usha
patients with solid tumors, especially women with ovarian carcinoma. 20 This possibility should also be considered when interpreting a germline result, especially when the allelic fraction of a mutation is <50%. We have shown that the TP53 mutation
Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma
Talia Golan and Pascal Hammel
2015 ; 33 : 244 – 250 . 10.1200/JCO.2014.56.2728 15. Gelmon KA , Tischkowitz M , Mackay H , Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Featured Updates to the NCCN Guidelines
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh
versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer
Ranjit Manchanda, Li Sun, Monika Sobocan, Isabel V. Rodriguez, Xia Wei, Ashwin Kalra, Samuel Oxley, Michail Sideris, Caitlin T. Fierheller, Robert D. Morgan, Dhivya Chandrasekaran, Kelly Rust, Pavlina Spiliopoulou, Rowan E. Miller, Shanthini M. Crusz, Michelle Lockley, Naveena Singh, Asma Faruqi, Laura Casey, Elly Brockbank, Saurabh Phadnis, Tina Mills-Baldock, Fatima El-Khouly, Lucy A. Jenkins, Andrew Wallace, Munaza Ahmed, Ajith Kumar, Elizabeth M. Swisher, Charlie Gourley, Barbara M. Norquist, D. Gareth Evans, and Rosa Legood
MI , Brady MF , Inherited mutations in women with ovarian carcinoma . JAMA Oncol 2016 ; 2 : 482 – 490 . 6. Kuchenbaecker KB , Hopper JL , Barnes DR , Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2
Update on Immunotherapy for Melanoma
Antoni Ribas
activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients . Proc Natl Acad Sci U S A 2003 ; 100 : 4712 – 4717 . 63. Phan GQ Yang JC Sherry RM . Cancer
Myeloid Growth Factors
Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, and Michael K. Wong
; 11 : 172 – 179 . 28 Numnum TM Kimball KJ Rocconi RP . Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer 2007 ; 17 : 1019 – 1024
New Therapies for Ovarian Cancer
David M. O’Malley
, . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial . Lancet 2017 ; 390 : 1949 – 1961 . 10.1016/S0140-6736(17)32440-6 28916367
NCCN News
recommendations,” said Dr. Morgan. The NCCN Guidelines continue to recommend that women with borderline epithelial ovarian cancer of low malignant potential be primarily surgically managed. In contrast to patients with frankly invasive ovarian carcinoma, women
Chemotherapy Hypersensitivity Reactions in Ovarian Cancer
Matthieu Picard, Ursula A. Matulonis, and Mariana Castells
. 13. Morgan JS Adams M Mason MD . Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma . Eur J Cancer 1994 ; 30A : 1205 – 1206 . 14. Navo M Kunthur A Badell ML . Evaluation of the incidence of
